Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. Kolitz JE, et al. Among authors: hurd dd. J Clin Oncol. 2004 Nov 1;22(21):4290-301. doi: 10.1200/JCO.2004.11.106. J Clin Oncol. 2004. PMID: 15514371 Clinical Trial.
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
Baer MR, George SL, Sanford BL, Mrózek K, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. Baer MR, et al. Leukemia. 2011 May;25(5):800-7. doi: 10.1038/leu.2011.9. Epub 2011 Feb 15. Leukemia. 2011. PMID: 21321569 Free PMC article.
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart CC, Hurd DD, Kolitz JE, Velez-Garcia E, Stone RM, Bloomfield CD, Schiffer CA, Larson RA. Szatrowski TP, et al. Among authors: hurd dd. Cancer. 2003 Mar 15;97(6):1471-80. doi: 10.1002/cncr.11219. Cancer. 2003. PMID: 12627512 Free article. Clinical Trial.
A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. Pardee TS, et al. Among authors: hurd dd. Clin Cancer Res. 2018 May 1;24(9):2060-2073. doi: 10.1158/1078-0432.CCR-17-2282. Epub 2018 Feb 6. Clin Cancer Res. 2018. PMID: 29437791 Free PMC article. Clinical Trial.
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD; Cancer and Leukemia Group B (CALGB). Langer C, et al. Blood. 2008 Jun 1;111(11):5371-9. doi: 10.1182/blood-2007-11-124958. Epub 2008 Mar 31. Blood. 2008. PMID: 18378853 Free PMC article. Clinical Trial.
Auto-SCT for AML in second remission: CALGB study 9620.
Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, Larson RA; Cancer and Leukemia Group B. Linker CA, et al. Bone Marrow Transplant. 2009 Sep;44(6):353-9. doi: 10.1038/bmt.2009.36. Epub 2009 Mar 16. Bone Marrow Transplant. 2009. PMID: 19289999
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA; Cancer and Leukemia Group B. Stone RM, et al. Leuk Res. 2011 Mar;35(3):329-33. doi: 10.1016/j.leukres.2010.07.017. Epub 2010 Aug 4. Leuk Res. 2011. PMID: 20688393 Free PMC article. Clinical Trial.
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Wetzler M, et al. Among authors: hurd dd. Leuk Lymphoma. 2008 Jul;49(7):1274-8. doi: 10.1080/10428190802043887. Leuk Lymphoma. 2008. PMID: 18452072 Free PMC article. Clinical Trial.
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).
Grinblatt DL, Yu D, Hars V, Vardiman JW, Powell BL, Nattam S, Silverman LR, de Castro C 3rd, Stone RM, Bloomfield CD, Larson RA; Cancer and Leukemia Group. Grinblatt DL, et al. Cancer. 2009 Jan 1;115(1):84-93. doi: 10.1002/cncr.23995. Cancer. 2009. PMID: 19025972 Free PMC article. Clinical Trial.
152 results